Compared with aspirin alone, aspirin plus warfarin (goal for international normalized ratio, 2-2.5) or warfarin alone (goal for international normalized ratio, 2.8-4.3) results in fewer re-infarctions and thromboembolic events. Treating 1000 patients for 1 year would result in approximately 10 fewer reinfarctions and 3 fewer strokes at a cost of 4 more major bleeding episodes. In addition, many patients will not be able to tolerate warfarin therapy. For highly motivated patients at low risk of bleeding, warfarin or warfarin plus aspirin is more effective than aspirin for secondary prevention of myocardial infarction.
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.Am Heart J. 2006 Nov;152(5):967-73. doi: 10.1016/j.ahj.2006.06.024. Am Heart J. 2006. PMID: 17070169
Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes.Am J Cardiol. 2007 Jun 15;99(12):1637-42. doi: 10.1016/j.amjcard.2007.01.052. Epub 2007 Apr 27. Am J Cardiol. 2007. PMID: 17560866
Aspirin and warfarin versus aspirin monotherapy after myocardial infarction.Ann Pharmacother. 2003 Oct;37(10):1502-5. doi: 10.1345/aph.1C474. Ann Pharmacother. 2003. PMID: 14519047 Review.
Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.J Invasive Cardiol. 2004 May;16(5):271-8. J Invasive Cardiol. 2004. PMID: 15152137 Review.
Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study.Am Heart J. 2004 Jul;148(1):e6. doi: 10.1016/j.ahj.2004.02.008. Am Heart J. 2004. PMID: 15215815 Clinical Trial.